| Name | Title | Contact Details |
|---|
The i/mx Companies is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
TBH is a leading provider of behavioral health services. We specialize in the treatment of children and adults with Autism Spectrum Disorders and developmental disabilities, using the principles of Applied Behavior Analysis (ABA). TBH is proud to employ a talented staff dedicated to its mission and values, constructing a team of experienced, caring and enthusiastic individuals to coordinate the best behavior program possible for children, adults and families. Further, TBH`s collaborative efforts mean that parents, schools, agencies, Supervisors and Skills Trainers all play important roles in behavior programs, forming a large team dedicated to the needs of each client. TBH employs many Board Certified Behavior Analysts, and each Behavioral Consultant, also known as a Supervisor, is carefully screened to meet the qualifications set forth by TBH as well as those of the Behavior Analyst Certification Board (BACB). Further, each Skills Trainer, also known as a Paraprofessional, is screened using the same criteria. Behavioral Consultants and Skills Trainers are selected for clients on a case-by-case basis with careful consideration given to education, level of experience, and personality compatibility with the family and child.
ScriptPro LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Mission, KS. To find more information about ScriptPro LLC, please visit www.scriptpro.com